112 related articles for article (PubMed ID: 9312815)
1. [New AIDS study confirms: triple combination therapy with the protease inhibitor indinavir lowers the risk of mortality by 50%].
Praxis (Bern 1994); 1997 May; 86(20):860. PubMed ID: 9312815
[No Abstract] [Full Text] [Related]
2. Undetectable HIV levels after triple therapy with indinavir.
AIDS Patient Care STDS; 1997 Jun; 11(3):193-4. PubMed ID: 11361795
[No Abstract] [Full Text] [Related]
3. ACTG 320 trial halted as three-drug arm proves superior.
AIDS Patient Care STDS; 1997 Jun; 11(3):194. PubMed ID: 11361796
[No Abstract] [Full Text] [Related]
4. Stavudine, lamivudine and indinavir in children with advanced HIV-1 infection: preliminary experience.
Monpoux F; Sirvent N; Cottalorda J; Mariani R; Lefbvre JC
AIDS; 1997 Oct; 11(12):1523-5. PubMed ID: 9342078
[No Abstract] [Full Text] [Related]
5. [Treatment of HIV infections and AIDS with protease inhibitor and two nucleoside analogs].
Jensen-Fangel S; Larsen L; Thomsen HF; Nielsen LP; Black FT; Obel N
Ugeskr Laeger; 1999 Mar; 161(12):1751-4. PubMed ID: 10210974
[TBL] [Abstract][Full Text] [Related]
6. Three drug combo halves AIDS deaths.
Treat Rev; 1997 Apr; (No 24):2-4. PubMed ID: 11364283
[TBL] [Abstract][Full Text] [Related]
7. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens.
Hogg RS; Yip B; Kully C; Craib KJ; O'Shaughnessy MV; Schechter MT; Montaner JS
CMAJ; 1999 Mar; 160(5):659-65. PubMed ID: 10102000
[TBL] [Abstract][Full Text] [Related]
8. Head-to-head study of protease inhibitors.
AIDS Patient Care STDS; 1998 Jan; 12(1):63-4. PubMed ID: 11361890
[No Abstract] [Full Text] [Related]
9. HAART therapy: dividing the epidemic?
Laurence J
AIDS Patient Care STDS; 1997 Dec; 11(6):397-8. PubMed ID: 11361859
[No Abstract] [Full Text] [Related]
10. Nevirapine-plus-protease studies under way.
AIDS Alert; 1996 Oct; 11(10):119. PubMed ID: 11363856
[TBL] [Abstract][Full Text] [Related]
11. Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy.
Mayer KH; Boswell S; Goldstein R; Lo W; Xu C; Tucker L; DePasquale MP; D'Aquila R; Anderson DJ
Clin Infect Dis; 1999 Jun; 28(6):1252-9. PubMed ID: 10451162
[TBL] [Abstract][Full Text] [Related]
12. [AIDS triple therapy. The gap between viral load and side effects].
Gürtler L
Fortschr Med; 1998 Sep; 116(27):4-5. PubMed ID: 9816747
[No Abstract] [Full Text] [Related]
13. Switching HIV-1 protease inhibitor therapy: which? When? And why?
Guardiola JM; Domingo P; Vazquez G
Arch Intern Med; 1999 Jan; 159(2):194-5. PubMed ID: 9927104
[No Abstract] [Full Text] [Related]
14. Brazil indinavir results releases.
AIDS Patient Care STDS; 1997 Dec; 11(6):457. PubMed ID: 11361873
[No Abstract] [Full Text] [Related]
15. [More transparency facilities drug choice in general practice. Booster regimens in direct comparison].
MMW Fortschr Med; 2002 Apr; 144 Suppl 1():82. PubMed ID: 12043090
[No Abstract] [Full Text] [Related]
16. Risk of new AIDS diseases in people on triple therapy.
Miller V; Staszewski S; Nisius G; Lepri AC; Sabin C; Phillips AN
Lancet; 1999 Feb; 353(9151):463. PubMed ID: 9989719
[No Abstract] [Full Text] [Related]
17. The end of AIDS?
Leland J
Newsweek; 1996 Dec; 128(23):64-8, 71, 73. PubMed ID: 10162943
[No Abstract] [Full Text] [Related]
18. Crixivan reduces viral load.
AIDS Patient Care STDS; 1996 Feb; 10(1):50. PubMed ID: 11361665
[No Abstract] [Full Text] [Related]
19. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy.
Burger DM; Hoetelmans RM; Hugen PW; Mulder JW; Meenhorst PL; Koopmans PP; Brinkman K; Keuter M; Dolmans W; Hekster YA
Antivir Ther; 1998; 3(4):215-20. PubMed ID: 10682141
[TBL] [Abstract][Full Text] [Related]
20. Twice-daily dosing Crixivan study discontinued.
WORLD; 1998 Oct; (No 90):7. PubMed ID: 11365922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
